BLASUBCUTANEOUSINJECTABLE
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ROLVEDON (eflapegrastim-xnst) by Spectrum Dynamics. Approved for breast cancer. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROLVEDON (eflapegrastim-xnst) is a long-acting granulocyte colony-stimulating factor (G-CSF) analog approved for chemotherapy-induced neutropenia in breast cancer patients. It stimulates the proliferation and differentiation of hematopoietic progenitor cells to increase neutrophil production. Administered as a single subcutaneous injection per chemotherapy cycle, it reduces infection risk during cancer treatment.
$662KPart D
PeakEarly-stage peak-phase product with modest Medicare utilization suggests small but growing field team focused on oncology-specialist sales channels.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications (1)
Career Relevance
Working on ROLVEDON positions you in Spectrum Dynamics' oncology-supportive care vertical, with emphasis on field-based sales and customer success roles in international markets. Career growth depends on market penetration in breast cancer centers and hematology/oncology specialist networks, with modest team size relative to blockbuster competitors.
Field Service Engineer
Worked on ROLVEDON at Spectrum Dynamics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.